Effect of zoledronic acid injection combined with radiopharmaceutical 89SrCI2 therapy on the growth and clinical symptoms of lung cancer bone metastasis

• Main Authors: Jia-Lun Zhu, Zhi-Yong Deng, Chuan-Zhou Yang
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-09-01
• Series: Journal of Hainan Medical University
• Subjects: Zoledronic acid injection; 89SrCI2; Lung cancer bone metastasis
• Online Access: http://www.hnykdxxb.com/PDF/201617/23.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To find the effect of zoledronic acid injection combined with radiopharmaceutical 89SrCI2 therapy on the growth and clinical symptoms of lung cancer bone metastasis. Methods: A total of 102 lung cancer patients with bone metastases were included in the study and randomly divided into observation group and control group (n=51) according to different treatment they received. Control group received zoledronic acid injection therapy alone, observation group received zoledronic acid injection combined with radiopharmaceutical 89SrCI2 therapy, and then differences in the growth of lung cancer bone metastasis, bone metabolism, tumor markers and alkaline phosphatase, pain score and pain-related mediator levels, etc. were compared between two groups. Results: Number of metastases of observation group after treatment was less than that of control group, and serum bone metabolism indexes OPG, BSP, TRACP-5b, ICTP and BAP levels, serum tumor markers CYFRA21-1, CEA, NSE, CA125 and BALP levels as well as serum pain-related mediators PGE2, ET-1 and TNF- 毩 levels were lower than those of control group (P<0.05). Conclusions: Zoledronic acid injection combined with radiopharmaceutical 89SrCI2 therapy can contain the growth of lung cancer bone metastasis, optimize bone metabolism state while alleviate patients’ perception of pain.